Medical device company
Appears in 1 story · Last updated Oct 26, 2026
Listed on ASX, commercializing Symphony in the US
Aroa Biosurgery published results from a randomized controlled trial showing its Symphony wound product heals diabetic foot ulcers faster than standard care. In the company's headline analysis, 55% of ulcers closed within 12 weeks with Symphony, versus 35% with standard care alone. The study appeared in the International Wound Journal.
Updated Oct 26
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
